Heart Attack Treatment (cont.)
Daniel Lee Kulick, MD, FACC, FSCAI
Daniel Lee Kulick, MD, FACC, FSCAI
Dr. Kulick received his undergraduate and medical degrees from the University of Southern California, School of Medicine. He performed his residency in internal medicine at the Harbor-University of California Los Angeles Medical Center and a fellowship in the section of cardiology at the Los Angeles County-University of Southern California Medical Center. He is board certified in Internal Medicine and Cardiology.
In this Article
Glycoprotein IIb/IIIa inhibitors
The glycoprotein IIb/IIIa inhibitors such as abciximab (Reopro) and eptifibatide (Integrilin) prevent aggregation of platelets by inhibiting the glycoprotein receptors on the platelets. They are the most potent antiplatelet agents, approximately 9 times more potent than aspirin, and 3 times more potent than the thienopyridines. The glycoprotein IIb/IIIa inhibitors are also the most expensive antiplatelet agents. The currently FDA-approved glycoprotein IIb/IIIa inhibitors have to be given intravenously. They usually are given along with aspirin and heparin. They are quick acting; their maximal antiplatelet effects are achieved within minutes of infusion. These inhibitors have become important in the treatment of patients with heart attacks, patients with unstable angina, and patients undergoing PTCA with or without stenting. Numerous studies have shown that glycoprotein IIb/IIIa inhibitors:
The major risk of glycoprotein IIb/IIIa inhibitors is bleeding. Therefore, patients on heparin, aspirin, and glycoprotein IIb/IIIa inhibitors have to be monitored closely for bleeding. Recent studies have demonstrated equal efficacy of abciximab and eptifibatide. Eptifibatide is shorter acting than abciximab. In the event of major bleeding, the antiplatelet effect of eptifibatide can be reversed within hours of stopping the intravenous infusion, while the antiplatelet effect of abciximab will last much longer. Sometimes, transfusions of platelets are necessary to treat major bleeding due to abciximab.
An uncommon side effect of glycoprotein IIb/IIIa inhibitors is the development of low platelet counts (thrombocytopenia). Thrombocytopenia can increase the risk for bleeding and, in rare instances, may actually cause blood to clot. Thus, patients receiving glycoprotein IIb/IIIa inhibitors should have their platelet counts monitored closely.
Reviewed by Jay W. Marks, MD on 8/24/2012
Viewers share their comments
Heart Attack - Experience Question: Please describe your experience with a heart attack.
Heart Attack - Symptoms Question: What were your heart attack symptoms?
Heart Attack Treatment - Aspirin Question: Do you take aspirin to prevent a first or second heart attack? Please share your experience.
Heart Attack Treatment - Types of Treatment Question: What kinds of treatment, procedures, surgeries, or medications have you received after experiencing a heart attack?
Heart Attack Treatment - Angiography or Angioplasty Question: Please discuss your experience with coronary angiography and PTCA.
Heart Attack Treatment - Coronary Artery Bypass Question: Did you have coronary artery bypass surgery? Please share your story.
Heart Attack Treatment - Preventing a Second Attack Question: If you've had a heart attack, what lifestyle changes have you made to prevent a second heart attack?
Get the latest health and medical information delivered direct to your inbox FREE!